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Abstract
Background We suggest that surgical extirpation of primary
breast cancer among other effects accelerates relapse for some
premenopausal node-positive patients. These accelerated
relapses occur within 10 months of surgery for untreated
patients. The mechanism proposed is a stimulation of
angiogenesis for distant dormant micrometastases. This has
been suggested as one of the mechanisms to explain the
mammography paradox for women aged 40–49 years. We
could imagine that it also plays a role in adjuvant chemotherapy
effectiveness since, perhaps not coincidentally, this is most
beneficial for premenopausal node-positive patients.
Hypothesis We speculate that there is a burst of angiogenesis
of distant dormant micrometastases after surgery in
approximately 20% of premenopausal node-positive patients.
We also speculate that this synchronizes them into a temporal
highly chemosensitive state and is the underlying reason why
adjuvant chemotherapy works particularly well for that patient
category. Furthermore, this may explain why cancer in younger
patients is more often 'aggressive'.
Testing the hypothesis Stimulation of dormant
micrometastases by primary tumor removal is known to occur in
animal models. However, we need to determine whether it
happens in breast cancer. Transient circulating levels of
angioactive molecules and serial high-resolution imaging
studies of focal angiogenesis might help.
Implications Short-course cytotoxic chemotherapy after
surgery has probably reached its zenith, and other strategies,
perhaps antiangiogenic methods, are needed to successfully
treat more patients. In addition, the hypothesis predicts that
early detection, which is designed to find more patients without
involved lymph nodes, may not be a synergistic strategy with
adjuvant chemotherapy, which works best with positive lymph
node patients.
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Background
We have previously suggested that the surgical extirpation
of primary breast cancer accelerates relapse [1]. Baum and
colleagues have made similar suggestions [2]. There are
two mechanisms that we have proposed: one is angiogenic
and the other is proliferative. Perhaps each also includes a
component of the other.
The angiogenic surge is due either to the removal of inhib-
itors or to the appearance of stimulators or growth factors
in response to surgical wounding [3,4]. This activation
causes temporarily dormant distant micrometastases to
vascularize, and thus to enter a rapid growth phase. Data
suggest that such stimulated angiogenesis may occur in
about 20% of premenopausal patients with node-positiveBreast Cancer Research    Vol 6 No 4    Retsky et al.
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disease. This is more frequent than in other groups; the fre-
quency is 5:1 for node-positive patients compared with
node-negative patients, and the frequency is 2:1 for pre-
menopausal patients compared with postmenopausal
patients. It is therefore mainly peculiar to premenopausal
node-positive patients. We have suggested that this
phenomenology can be important to explain the breast
cancer screening controversy for women aged 40–49
years [5-7].
The proliferative mechanism for early relapse, which is also
the result of surgery, is stimulated division of single dor-
mant cells [8] or even changes in the dynamics maintaining
the steady state of dormant or indolent micrometastases,
eventually resulting in angiogenesis and growth. For small
primary breast tumors less than 2 cm, 50% of all relapses
are in this first wave of relapses. For larger tumors, 75–
83% of relapses are in that category.
The early relapses among patients receiving no adjuvant
treatment due to stimulated angiogenesis occur in the first
10 months after surgery, while the adverse events stimu-
lated by proliferative changes occur in the first 4 years after
surgery with a peak at 18 months. There is thus overlap
between these two distributions of outcome variance.
Together, these distributions constitute an early peak in
relapses that happens sooner than would otherwise occur
due to a stimulation of growth from surgery.
We wondered what effect adjuvant chemotherapy had on
these early relapse events. In particular, one could imagine
that chemotherapy would attenuate surgery-stimulated
tumor cell proliferation and tumor growth. Since this sur-
gery-stimulated growth is strongest just after operation,
when adjuvant chemotherapy is traditionally used, a high
level of cytotoxic activity on these rapidly proliferating cells
would be expected. We hypothesized that there should be
some clear clinical evidence demonstrating an intimate tie
between surgery-stimulated tumor growth and adjuvant
chemotherapy.
We analyzed the frequency and timing of post-resection
relapse in comparable populations that did receive and did
not receive adjuvant chemotherapy, focusing upon the time
structure of early recurrence during the first 4 years after
resection. Figure 1 shows the hazard of relapse for
untreated patients and for patients treated with Bonadonna
cyclophosphamide, methotrexate and fluorouracil chemo-
therapy [9]. The reduction in relapse hazard with cyclo-
phosphamide, methotrexate and fluorouracil therapy for
premenopausal node-positive patients is approximately
80% at 6 months, 50% at 1.5 years and 10–20% at 4–7
years. The advantage of cyclophosphamide, methotrexate
and fluorouracil chemotherapy is seen to be most pro-
nounced in either delaying relapses or curing patients who
would have relapsed in the first year or so.
Following early trials, chemotherapy clinical consensus
reports from the years shortly after the introduction of adju-
vant chemotherapy for breast cancer (1980 and 1985
National Institutes of Health Consensus Development Con-
ferences) recommended using adjuvant chemotherapy for
premenopausal node-positive patients [10]. Only in later
years, after careful analysis of much larger trials with longer
follow-up, was it determined that adjuvant chemotherapy is
of some value in subsets of node-negative disease, or in
any patient with positive nodes.
Comparing this historical development of adjuvant chemo-
therapy use with our model, we wondered whether there
might be a connection between induced angiogenesis at
surgery and adjuvant chemotherapy, since they are each
closely linked to early relapses of premenopausal node-
positive patients.
Presentation of hypothesis
We speculate that we have identified the underlying reason
why adjuvant chemotherapy was initially indicated only for
premenopausal node-positive breast cancer patients.
Removal of the primary tumor stimulates angiogenesis in
distant dormant micrometastases in a substantial fraction
of patients in that subgroup. This surgery-induced activa-
tion results in a release from dormancy and in a rapid
growth of micrometastases and corresponding high chem-
osensitivity just at the time when adjuvant chemotherapy
Figure 1
Hazard rate for treatment failure for axillary node-positive patients  undergoing mastectomy alone (continuous line), or followed by adju- vant chemotherapy according to the cyclophosphamide, methotrexate  and fluorouracil original scheme for 6–12 months (dashed line) Hazard rate for treatment failure for axillary node-positive patients 
undergoing mastectomy alone (continuous line), or followed by adju-
vant chemotherapy according to the cyclophosphamide, methotrexate 
and fluorouracil original scheme for 6–12 months (dashed line). Curves 
are based on a logistic model [13].Available online http://breast-cancer-research.com/content/6/4/R372
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was empirically determined to be most effective. This also
may be why breast cancer in young women is called
'aggressive'. Indeed, the term is well fitting for the 20% of
premenopausal node-positive patients that relapse within 1
year of surgery.
Testing the hypothesis
Our hypothesis for breast cancer is supported by what hap-
pens in the Lewis lung animal model [3], in which 100% of
mice injected with this tumor develop many lung microme-
tastases that do not vascularize and grow while the primary
tumor is intact. After the primary tumor is resected, the ang-
iogenic switch is thrown and the lung metastases start to
grow rapidly.
Our analysis suggests this also happens in breast cancer,
but only in one or two micrometastases per patient in 5–
6% of all premenopausal patients (or in 20% of all premen-
opausal node-positive patients). Testing whether this hap-
pens in breast cancer will be relatively difficult because of
the fewer events and clinical limitations. Circulating levels
of known angioactive molecules (both stimulators and
inhibitors) could be measured before and after surgery to
look for indirect signs of the hypothesized phenomenon.
Direct observation of angiogenesis switch-on is much more
difficult, and specific advances of high-resolution functional
imaging methodology, aimed to study focal angiogenesis
within major sites of recurrence, are needed.
Implications
There are two major implications. First, the early use of
adjuvant chemotherapy in 1975 cured approximately an
additional 11% of premenopausal node-positive patients
(20-year disease-free survival was 37% for treated patients
and was 26% for untreated patients) [9]. Over the years
since then some improvements have been made, but not
dramatically so, and it may be said that results of adjuvant
chemotherapy have plateaued [11]. Our hypothesis would
suggest that it would be difficult to cure more than 20% of
premenopausal node-positive patients with short-course
and intensive chemotherapy after surgery. To cure more
patients, other strategies would be needed to take advan-
tage of the complex tumor kinetics including host
interactions.
The second implication is that early detection, which is
designed to find more node-negative patients, may not be
a strategy for which adjuvant chemotherapy can add much
to outcome, since it works best with node-positive patients.
This may explain the disappointing lack of benefit reported
from early detection of breast cancer by the Canadian
Screening study in which all premenopausal node-positive
patients received adjuvant chemotherapy [12].
Other than patients that are premenopausal and node-pos-
itive, patients who are diagnosed with estrogen receptor-
negative cancers are also highly responsive to adjuvant
chemotherapy. Unfortunately the Milan data [1,6,9,13] did
not contain receptor values for individual patients, so
understanding any possible relation between our hypo-
thesis and hormone receptors must await further
developments.
There is apparently a complex interaction among screening,
surgery, adjuvant therapy, angiogenesis, tumor cell prolifer-
ation, nodal status and menopausal status that needs to be
better understood for further enhancing breast cancer
care. These effects seem to be more pronounced, and thus
particularly important, for younger women.
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